Oncology Medical News about Melanoma Melanoma, Amelanotic

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Over-the-Counter Nanotech Test for Prostate Cancer Anticipated

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Positron emission tomography in early detection of relapse in high-risk melanoma patients: a retrospective review
Community Oncology , 10/09/09

Kottschade LA et al. – To determine the usefulness of FDG–PET in the surveillance of melanoma patients at high risk of relapse, the authors reviewed the medical records of 667 high–risk patients who had FDG–PET imaging and were seen at the Mayo Clinic between 1999 and 2007. Serial FDG–PET imaging for high–risk melanoma patients may be a useful tool for early identification of asymptomatic relapse amenable to complete surgical resection.

<< Previous
Carotid Body Tumors: Advantages of Contrast Ultrasound...

Next >>
BRCA1/2 testing in patients with newly diagnosed breast cancer